CWM
GSK icon

Centric Wealth Management’s GSK GSK Stock Holding History

Centric Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,184
Closed -$228K – 139
2022
Q1 		$228K Buy
4,184
+74
+2% +$4.02K 0.07% 141
2021
Q4 		$227K Sell
4,110
-1,268
-24% -$66K 0.07% 142
2021
Q3 		$257K Sell
5,378
-232
-4% -$11.7K 0.09% 132
2021
Q2 		$279K Sell
5,610
-1,772
-24% -$85.1K 0.1% 121
2021
Q1 		$329K Buy
7,382
+39
+0.5% +$1.77K 0.09% 164
2020
Q4 		$338K Buy
7,343
+3,157
+75% +$145K 0.11% 148
2020
Q3 		$216K Buy
+4,186
New +$210K 0.16% 101
2020
Q2 		– Sell
-4,186
Closed -$216K – 149
2020
Q1 		$216K Sell
4,186
-164
-4% -$8.75K 0.16% 101
2019
Q4 		$256K Buy
4,350
+164
+4% +$9.12K 0.2% 76
2019
Q3 		$216K Buy
4,186
+46
+1% +$2.37K 0.16% 101
2019
Q2 		$207K Buy
4,140
+74
+2% +$3.71K 0.18% 99
2019
Q1 		$212K Buy
+4,066
New +$203K 0.2% 88

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Centric Wealth Management's GSK Position: Q2 2022 in Review

Centric Wealth Management sold out of GSK (GSK) in Q2 2022, closing a stake of 4,184 shares — an estimated $228K sold.

Centric Wealth Management first reported a position in GSK in Q1 2019 and held it in 12 quarters. The position peaked at $338K in Q4 2020. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

  • Centric Wealth Management reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
  • Centric Wealth Management sold 4,184 GSK shares in Q2 2022, an estimated $228K.
  • Centric Wealth Management first reported a position in GSK in Q1 2019 and held it in 12 quarters.
  • Centric Wealth Management's GSK position peaked at $338K in Q4 2020.
  • 900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Centric Wealth Management's 13F filing for Q2 2022, filed 6 Jul 2022.